Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Board Chairman

Effective January 26, 2022, the Meridian Bioscience, Inc. Board of Directors (the "Board") elected John C. McIlwraith as Chairman of the Board, succeeding David C. Phillips upon his retirement from the Board. The Company issued a press release on January 27, 2022 related to Mr. McIlwraith's election as Chairman. A copy of the release is furnished herewith as Exhibit 99.1.

Board Committees

Effective January 26, 2022, the Board re-constituted its committees as follows:

Audit

Felicia Williams (Chair); James M. Anderson; Anthony P. Bihl III; John C. McIlwraith (Ex-Officio)

Compensation

James M. Anderson (Chair); Anthony P. Bihl III; Catherine A. Sazdanoff; John C. McIlwraith (Ex-Officio)

Nominating and Corporate Governance

Catherine A. Sazdanoff (Chair); Dwight E. Ellingwood; John M. Rice, Jr.; John C. McIlwraith (Ex-Officio)

Item 5.07 Submission of Matters to a Vote of Security Holders

At the January 26, 2022 Annual Meeting (the "Meeting") of the shareholders of Meridian Bioscience, Inc. (the "Company"), shareholders voted on the matters set forth below.





    (a)  Shareholders elected the eight nominees identified in Item 1 of the Proxy
         Statement based upon the following votes:




Name                         For           Withheld        Broker Non-Votes
James M. Anderson          34,287,712       1,214,965              3,432,570
Anthony P. Bihl III        35,083,075         419,602              3,432,570
Dwight E. Ellingwood       34,341,228       1,161,449              3,432,570
Jack Kenny                 35,307,028         195,649              3,432,570
John C. McIlwraith         35,252,584         250,093              3,432,570
John M. Rice, Jr.          35,122,751         379,926              3,432,570
Catherine A. Sazdanoff     34,032,863       1,469,814              3,432,570
Felicia Williams           35,258,337         244,340              3,432,570




    (b)  Shareholders ratified the Audit Committee's appointment of Ernst & Young
         LLP as the Company's Independent Registered Public Accountants for fiscal
         2022 based upon the following votes:




   For       Against   Abstain
38,705,001   214,839   15,407

(c) Shareholders approved, on an advisory basis, the compensation of the Company' named executive officers, based upon the following votes:





   For       Against   Abstain   Broker Non-Votes
34,490,496   922,525   89,656       3,432,570


Item 9.01.  Financial Statements and Exhibits.



(d) Exhibits




99.1      Press Release dated January 27, 2022

104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses